ESTRADIOL AND NORETHINDRONE ACETATE Drug Patent Profile

When do Estradiol And Norethindrone Acetate patents expire, and when can generic versions of Estradiol And Norethindrone Acetate launch?

Estradiol And Norethindrone Acetate is a drug marketed by Barr, Breckenridge Pharm, Naari Pte, Novast Labs, Teva Pharms Usa, and Xiromed. and is included in six NDAs.

The generic ingredient in ESTRADIOL AND NORETHINDRONE ACETATE is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Estradiol And Norethindrone Acetate

A generic version of ESTRADIOL AND NORETHINDRONE ACETATE was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17^th, 2008.

Summary for ESTRADIOL AND NORETHINDRONE ACETATE

US Patents:	0
Applicants:	6
NDAs:	6
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	38
Patent Applications:	106
DailyMed Link:	ESTRADIOL AND NORETHINDRONE ACETATE at DailyMed

Recent Clinical Trials for ESTRADIOL AND NORETHINDRONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	PHASE3
ViiV Healthcare	PHASE1
Bio Genuine (Shanghai) Biotech Co., Ltd.	Phase 3

See all ESTRADIOL AND NORETHINDRONE ACETATE clinical trials

Pharmacology for ESTRADIOL AND NORETHINDRONE ACETATE

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for ESTRADIOL AND NORETHINDRONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	ESTRADIOL AND NORETHINDRONE ACETATE	estradiol; norethindrone acetate	TABLET;ORAL	079193-001	May 11, 2010	AB	RX	No	No
Teva Pharms Usa	ESTRADIOL AND NORETHINDRONE ACETATE	estradiol; norethindrone acetate	TABLET;ORAL	200747-001	Mar 8, 2012		DISCN	No	No
Naari Pte	ESTRADIOL AND NORETHINDRONE ACETATE	estradiol; norethindrone acetate	TABLET;ORAL	210233-001	Feb 28, 2018	AB	RX	No	No

Market Dynamics and Financial Trajectory for ESTRADIOL AND NORETHINDRONE ACETATE

Last updated: February 27, 2026

What Drives Demand and Supply of Estradiol and Norethindrone Acetate?

The combination of estradiol and norethindrone acetate is primarily used for hormone replacement therapy (HRT), oral contraceptives, and menopausal symptom management. Its market is influenced by demographic trends, regulatory landscapes, and competitive dynamics.

Key Market Drivers

• Aging populations in North America and Europe increase demand for menopausal therapies.
• Growing awareness of women's health fosters increased contraceptive use.
• Advances in drug formulation enhance bioavailability and reduce side effects, increasing physician preference.
• Regulatory approvals expand indications, creating new markets.

Supply Factors

• Major pharmaceutical companies such as Pfizer, Allergan, and Teva manufacture products containing these ingredients.
• API (active pharmaceutical ingredient) production capacity influences supply stability.
• Patent statuses affect market exclusivity; patent cliffs tend to introduce generic competition.

Market Size and Revenue Projections

The global market for combined estrogen and progestin therapies, including estradiol and norethindrone acetate formulations, reached approximately USD 10 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4% from 2023 to 2028.

Year	Estimated Market Size (USD billion)
2023	10.4
2024	10.8
2025	11.2
2026	11.7
2027	12.2
2028	12.7

Most revenue derives from North America (around 40%), followed by Europe (25%), Asia-Pacific (20%), and other regions (15%).

Revenue Breakdown by Indication (estimates for 2023)

• Menopausal symptom management: 60%
• Contraceptive use: 25%
• Other (e.g., osteoporosis, hormone therapy for transgender): 15%

Key Players and Market Shares

Company	Market Share (2023)	Main Products
Pfizer	35%	Premarin, Activella
Gedeon Richter	20%	Femoston, Gynodiol
Teva	15%	Estradiol/Norethindrone formulations
Others	30%	Numerous generics and regional brands

Regulatory and Patent Landscape

• Patent expirations for key branded formulations occurred between 2018 and 2022, leading to increased generic entry.
• The FDA approved multiple generic versions of estradiol/norethindrone products in recent years, reducing prices.
• Countries with evolving drug registration regulations tend to see delayed or accelerated entry of generics.

Competitive Challenges

• The rise of bioidentical hormone therapies and compounded formulations presents competition.
• Safety concerns linked to hormone therapy influence prescribing practices and patient preferences.
• Cost reductions from generic competition exert downward pressure on pricing and margins.

Technological and Innovation Trends

• Development of transdermal patches and subcutaneous implants offer alternatives.
• Long-acting formulations reduce dosing frequency and improve compliance.
• Biotechnology advances aim to improve safety profiles and reduce adverse effects.

Financial Outlook

Profitability margins are narrowing due to intense generic competition. While revenue growth is steady, margins may decline from an average of 25% pre-2018 to 15-20% post-generic entry.

Revenue estimates for leading products:

Product	2023 Revenue (USD million)	Estimated CAGR (2023-2028)
Premarin	500	1-2%
Femoston	150	3-4%
Generic formulations	300	5-6%

Conclusion

The market for estradiol and norethindrone acetate remains robust but faces pressures from patent expiration, generic entries, and alternative therapies. Growth is mainly driven by aging demographics and increasing women's health awareness, but profit margins will likely compress. Innovating delivery mechanisms and expanding indications are key strategies for sustained financial performance.

---

Key Takeaways

• Market expected to grow at 4% CAGR through 2028, reaching approximately USD 12.7 billion.
• Highly consolidated market with Pfizer and Gedeon Richter holding significant shares.
• Patent expirations and generic entries exert downward price pressure.
• Innovation in delivery systems and expanding indications remain strategic priorities.
• Financial margins are declining post-generic entry, though revenue remains steady.

---

FAQs

1. How does patent expiry influence market dynamics for this drug combination?
Patent expiry introduces generic competition, leading to price reductions and increased market penetration of lower-cost options.

2. What regions are experiencing the fastest growth?
The Asia-Pacific region is increasing its market share due to expanding healthcare infrastructure and rising hormone therapy demand.

3. Are there any significant regulatory barriers?
Regulatory requirements vary; some countries delay approval of generics, while others facilitate rapid entry post-patent expiration.

4. What alternative therapies are impacting demand?
Bioidentical hormone therapy, compounded formulations, and non-hormonal menopause treatments are competitors affecting demand.

5. How are innovation trends expected to influence future revenue?
Novel delivery methods and expanded indications can create premium-priced products, offsetting margin declines from generics.

---

References

[1] MarketResearch.com. (2023). Hormone Replacement Therapy Market Report.
[2] IQVIA. (2022). Global Pharmaceutical Market Trends.
[3] U.S. Food and Drug Administration. (2022). List of Approved Generic Drugs.
[4] Gedeon Richter. (2023). Corporate Annual Report.
[5] Pfizer. (2022). Product Portfolio Overview.